These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37705321)

  • 21. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
    Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
    Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents.
    Hoch M; Huth F; Sato M; Sengupta T; Quinlan M; Dodd S; Kapoor S; Hourcade-Potelleret F
    Clin Transl Sci; 2022 Jul; 15(7):1698-1712. PubMed ID: 35616006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Prakash C; Fan B; Ke A; Le K; Yang H
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
    Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
    Patel M; Chen J; McGrory S; O'Gorman M; Nepal S; Ginman K; Pithavala YK
    Invest New Drugs; 2020 Feb; 38(1):131-139. PubMed ID: 31728714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
    Tachibana M; Matsuki S; Toyama K; Maekawa Y; Fukae M; Shimizu T; Tsutsumi J; Shinohara S; Ishizuka H
    Clin Pharmacol Drug Dev; 2024 Jan; 13(1):77-86. PubMed ID: 37565616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults.
    Cox DS; Van Eyck L; Pawlak S; Beckerman B; Linn C; Ginman K; Thay Cha Y; LaBadie RR; Shi H; Damle B
    Br J Clin Pharmacol; 2023 Sep; 89(9):2867-2876. PubMed ID: 37184075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
    Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.
    Malhi V; Colburn D; Williams SJ; Hop CE; Dresser MJ; Chandra P; Graham RA
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):41-9. PubMed ID: 27154174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers.
    Hu C; Zhang Y; Pei T; Liu P; Zhang L
    Cancer Chemother Pharmacol; 2023 Jun; 91(6):523-529. PubMed ID: 37166499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the CYP3A and CYP2B6 Drug-Drug Interaction Potential of Lemborexant.
    Landry I; Aluri J; Nakai K; Hall N; Miyajima Y; Ueno T; Dayal S; Filippov G; Lalovic B; Moline M; Reyderman L
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):681-690. PubMed ID: 33455055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.
    Hu X; Hsieh CY; Zhang Y; Liu W; Xu S; Cai SX; Liu L; Zhang M; Shi H; Zhang H; Liu P; Li X; Xu P
    Br J Clin Pharmacol; 2023 Jun; 89(6):1767-1779. PubMed ID: 36458825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase 1, Open-Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.
    Trivedi A; Mather O; Vega S; Hutton S; Hellawell J; Lee E
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):849-856. PubMed ID: 35247290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
    Zhang Z; Gao X; Zhang P; Li Y; Fu M; Lin H; Feng S; Shen K; Yu G; Li X
    Br J Clin Pharmacol; 2023 Aug; 89(8):2561-2568. PubMed ID: 37005376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Cytochrome P450 3A and P-glycoprotein Drug-Drug Interaction Potential of Futibatinib.
    Yamamiya I; Hunt A; Takenaka T; Sonnichsen D; Mina M; He Y; Benhadji KA; Gao L
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):966-978. PubMed ID: 37132707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy.
    Chen B; Zhou D; Wei H; Yotvat M; Zhou L; Cheung J; Sarvaria N; Lai R; Sharma S; Vishwanathan K; Ware J
    Br J Clin Pharmacol; 2022 Aug; 88(8):3716-3729. PubMed ID: 35165925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
    Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.